stockportfolio.pro
Stocks / AKTS vs AZTA
AKTS vs AZTA
Aktis Oncology, Inc. and Azenta, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Aktis Oncology, Inc. (AKTS) | Azenta, Inc. (AZTA) | |
|---|---|---|
| Market cap | $1.0B | $1.0B |
| Revenue (latest FY) | $6.50M | $593.82M |
| Net income (latest FY) | $-63.73M | $-59.50M |
| Revenue growth (5y CAGR) | — | 8.9% |
| Net margin | -980.9% | -10.0% |
| Return on equity | 43.6% | -3.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 6 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AKTS — free Open AZTA — freeFrequently asked questions
Which is bigger, AKTS or AZTA?
Azenta, Inc. is larger by market capitalization — $1.0B versus $1.0B.
Which grows faster, AKTS or AZTA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.